Study wrapper · #440
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
Editor's note
A network meta-analysis pooling 25 randomized trials and 12 interventions to compare advanced anti-obesity agents. Tirzepatide 15 mg produced the greatest percent weight reduction (mean difference -17.97%), with CagriSema close behind (-17.84%) and semaglutide 7.2 mg at -14.66%; at the >=20% weight-loss threshold CagriSema and tirzepatide 15 mg led. Gastrointestinal adverse events rose with all treatments, while serious adverse events were comparable to placebo. As a meta-analysis of RCTs this sits near the top of the evidence hierarchy, and the ranking of tirzepatide and semaglutide is consistent with the broader trial record. The main caveats are inherent to network meta-analysis: it mixes indirect comparisons across trials with differing populations and durations, so the precise numeric ordering (especially tirzepatide vs CagriSema) carries uncertainty. The authors note no direct head-to-head data exist and call for them. Strong, well-grounded synthesis.
Plain-language abstract
Researchers combined the results of 25 separate randomized trials to compare several newer weight-loss drugs, since few have been tested directly against each other. They looked at how much weight people lost, how many reached large weight-loss targets, and side effects. Tirzepatide at 15 mg produced the largest average weight reduction (about 18%), with the combination drug CagriSema very close behind, and semaglutide also producing substantial loss. For losing 20% or more of body weight, CagriSema and high-dose tirzepatide were the standouts. Stomach and bowel side effects such as nausea became more common with all the drugs as doses increased, but serious side effects were no more frequent than with placebo. Because this analysis pools trials with different patients and lengths and compares many drugs indirectly, the exact ranking should be read with some caution. The authors conclude these dual-action and combination drugs are strong options and call for head-to-head trials to confirm the order.